ArriVent inks multi-target ADC collaboration with Alphamab

USA-based ArriVent BioPharma (Nasdaq: AVBP) has entered into a collaboration agreement with a unit of Chinese biotech Alphamab Oncology (HKG: 9966), to discover, develop and commercialize novel antibody-drug conjugates (ADCs) for the treatment of cancers.

The deal provides further evidence that US biotechs are not being deterred from signing licensing deals Chinese peers, some of which are deemed a threat to national security, and which the US government is trying to curb with its BIOSECURE Act.

“This exciting collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programs and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe,” said Bing Yao, chairman and chief executive of ArriVent. “We look forward to complementing the research and discovery capabilities of Alphamab with our global drug development and commercialization expertise to address the unmet needs of cancer patients,” he added.